1. Home
  2. SCLX vs BSEM Comparison

SCLX vs BSEM Comparison

Compare SCLX & BSEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scilex Holding Company

SCLX

Scilex Holding Company

N/A

Current Price

$5.86

Market Cap

55.1M

Sector

Health Care

ML Signal

N/A

BSEM

BioStem Technologies Inc. Common Stock

N/A

Current Price

$3.63

Market Cap

59.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SCLX
BSEM
Founded
2011
N/A
Country
United States
United States
Employees
N/A
2
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
55.1M
59.6M
IPO Year
2020
2026

Fundamental Metrics

Financial Performance
Metric
SCLX
BSEM
Price
$5.86
$3.63
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
59.5K
151.8K
Earning Date
04-10-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$30,253,000.00
N/A
Revenue This Year
$122.52
N/A
Revenue Next Year
$186.30
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.20
$2.25
52 Week High
$34.27
$4.66

Technical Indicators

Market Signals
Indicator
SCLX
BSEM
Relative Strength Index (RSI) 33.68 38.56
Support Level $5.48 $2.25
Resistance Level $7.77 N/A
Average True Range (ATR) 0.42 0.50
MACD -0.08 -0.02
Stochastic Oscillator 13.24 52.57

Price Performance

Historical Comparison
SCLX
BSEM

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

About BSEM BioStem Technologies Inc. Common Stock

BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.

Share on Social Networks: